Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: Prolonged remissions induced

Netherlands Journal of Medicine

Volumn 65, Issue 5, 2007, Pages 178-184

  van Dorp, S ^a   Meijer, E ^a   van de Donk, N W C J ^a   Dekker, A W ^a   Nieuwenhuis, K ^a   Minnema, M C ^a   Petersen, E ^a   Schutgens, R ^a   Verdonck, L F ^a   Lokhorst, H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Myeloma; Nonmyeloablative allogeneic stem cell transplantation

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; DACLIZUMAB; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NETHERLANDS; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OUTCOMES RESEARCH; OVERALL SURVIVAL; RADIATION DOSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; T CELL DEPLETION; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NETHERLANDS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34547497948     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Arora M, McGlave PB, Burns LJ, et al. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma. Bone Marrow Transplant 2005;35:1133-40.
2. Alyea EP, Weller E, Schlossman R, et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant 2003;32:1145-51.
3. Reynolds C, Ratanatharathorn V, Adams P, et al. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 2001;27:801-7.
4. Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996;88:4711-8.
5. Lokhorst HM, Segeren CM, Verdonck LF, et al. Dutch-Belgian Hemato-Oncology Cooperative Group. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol 2003;21:1728-33.
6. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004;104:961-8.
7. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoetic cell transplantation for patients older than 50 years of age. Blood 2005;105:1810-4.
8. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102(9):3446-54.
9. Gerull S, Goerner M, Benner A, et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005;36:963-9.
10. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
11. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft vs. host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17.
12. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
13. Corradini P, Cavo M, Lokhorst H, et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003;102:1927.
14. van de Donk NWCJ, Kröger N, Hegenbart U, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma [letter]. Blood 2006;107:3415-6.
15. van de Donk NW, Kroger N, Hegenbart U, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;12:1135-41.
16. Zeiser R, Finke J. Allogeneic haematopoietic cell transplantation for multiple myeloma: Reducing transplant-related mortality while harnessing the graft-versus-myeloma effect. Eur J Cancer 2006;42:1601-11.
17. Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100:755-6.
18. Garban F, Attal M, Michallet M, et al for the Intergroupe Francophone du Myélome and the Swiss Group for Clinical Cancer Research. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474-80.
19. Lokhorst HM. No RIC in high-risk myeloma? Blood 2006;107:3420-1.
20. Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004;103:4362-4.
21. Kröger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004;104:3361-3.